ClinicalTrials.gg
CompletedNCT01673919Updated Sep 12, 2025Results posted

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study

A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 4 sites in France. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.

Enrollment
18th of 21
7 · median 52
Started
2012
with 3 others
Phase 3
12 of 21
1 open now
Registered
12th of 21
by date
Lead sponsor
12 of 21
Hoffmann-La Roche

Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 18th largest by enrollment, is one of 4 that started in 2012, is one of 12 in phase 3, and was the 12th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tocilizumab in Arthritis, Juvenile, or all of them as a file.
02

Study summary

This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study. Patients will continue to receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed visit 33 (week 104) of WA19977 study and who may benefit from study drug treatment according to the investigator's assessment
  • Patients have to receive the first RoActemra/Actemra infusion in this study at the Week 8 visit at the latest
  • Females of and males with female partners of child-bearing potential must agree to use effective as defined by protocol

Exclusion criteria

Exclusion Criteria:

  • Patients with, according to investigator judgment, not satisfactory benefit from RoActemra/Actemra therapy within WA19977
  • Treatment with any agent since the last administration of study drug in the core study WA19977
  • Patient developed any other rheumatic disease or overlap syndrome other than the permitted polyarticular-course Juvenile Idiopathic Arthritis (JIA) subsets: rheumatoid factor positive or negative JIA or extended oligoarticular JIA
  • Patient is pregnant , lactating, or intending to become pregnant during the study and up to 12 weeks after the last administration of study drug
  • Any significant concomitant disease or medical or surgical condition
  • History of significant allergic or infusion reactions to prior biologic therapy
  • Currently active primary or secondary immunodeficiency
  • Any infections with to RoActemra/Actemra therapy according to investigator judgment
  • Inadequate hepatic, renal or bone marrow function
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    RoActemra/Actemra

    Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 mg/kg iv every 4 weeks, 104 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Events and Any Serious Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.

    Time frame: Approximately 2 years

  2. Number of Participants With Adverse Events of Special Interest

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. The AEs of special interests included gingival bleeding, tooth abscess, acarodermatitis, ear infection, gastroenteritis, herpes zoster ophthalmic, lice infestation, nasopharyngitis, oral fungal infection, oral herpes, pharyngitis, rhinitis, sinusitis, tonsillitis, tracheitis, tracheobronchitis, urinary tract infection, menorrhagia, asthma, epistaxis, and hematoma.

    Time frame: Approximately 2 years

  3. Number of Participants With Adverse Events Related to Tocilizumab

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. Relatedness of any AEs was reported as possibly related, probably related, or remotely related to TCZ.

    Time frame: Approximately 2 years

Secondary outcomes

  1. Mean Exposure to Study Treatment

    Participants received TCZ for Week 104 or when TCZ was commercially available for pcJIA participants, whichever comes first in France. The mean TCZ exposure (time from first to last administration) was reported.

    Time frame: Approximately 2 years

  2. Mean Duration of Study Follow-Up

    The participants were followed-up from Day 1 to last visit date (approximately 2 years). Mean time for which participants were followed up in the study was reported.

    Time frame: Approximately 2 years

  3. Number of Participants With AEs Leading to TCZ Modification, AEs Leading to Death, Anaphylaxis or Serious Hypersensitivity and Deaths

    Number of participants with AEs leading to TCZ modification, AEs leading to death, anaphylaxis or serious hypersensitivity, and deaths were reported.

    Time frame: Approximately 2 years

  4. Number of Participants With Clinically Significant Abnormal Laboratory Parameters

    Clinically significant abnormal parameters included eosinophil count, alanine aminotransferase, total bilirubin, and protein and blood in urine. Number of participants with these abnormal lab parameters was reported.

    Time frame: Approximately 2 years

  5. Number of Participants With Abnormality in Physical Examinations

    Participants with abnormal physical examinations of ear, nose and throat (asthma); extremities (synovitis, sequelae with flexion of the 5th right proximal interphalangeal joint, hallux valgus, deviations of metatarsophalangeal joints, and callus under metatarsal head); lung (mild bronchospasm); skin (vitiligo and hematoma, fatty subcutaneous infiltration on the neck, cutaneous eruption, and scalp pediculosis); and musculoskeletal system (discomfort in right hip) were reported.

    Time frame: Approximately 2 years

  6. Number of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology Response 50/70

    The Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) is comprised of six components: Maximum number of joints with active arthritis; Number of joints with limitation of movement; Erythrocyte Sedimentation Rate (ESR) and/or C-reactive Protein (CRP); Childhood Health Assessment Questionnaire-Disease Index (CHAQ-DI) graded on 4-point scales \[0 = without any difficulty and 3 = unable to do\] of 30 items grouped into 8 domains of physical function; Physician's global assessment of disease activity and Participant's global assessment of overall well-being (both assessed on a 0 to 100 mm Visual Analogue Scale \[VAS\], where score 0 = inactive arthritis and 100 = very active arthritis). A JIA ACR50/70 response is defined as improvement in at least three of the six core components by at least 50 percent (%), or 70%, respectively and no more than one of the remaining core components worsening by more than 30%.

    Time frame: Weeks 12, 24, 36, 48, 60, 72, 84, and 108

  7. Number of Participants With Inactive Disease

    Inactive disease was defined as: 1) No joints with active arthritis (no swollen, painful and lack of motion joints), 2) No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, 3) No active uveitis, 4) ESR and/or CRP within normal range, and 5) No disease activity according to Physician's global assessment of disease activity (\<= 10 millimeters \[mm\] on a VAS). The participant's treating physician provided a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale where score 0 represented 'arthritis inactive' (i.e., symptom-free and no arthritis symptoms) and score 100 represented 'arthritis very active'.

    Time frame: Weeks 24, 36, 48, 72, and 108

  8. Number of Participants Achieving Clinical Remission

    Clinical remission was defined as inactive disease observed for at least 6 continuous months. Clinical remission was defined as per medication uptake as: Level 1 (clinical remission on medication), Level 2 (clinical remission off oral corticosteroid medication \[still on TCZ\]), Level 3 (clinical remission off both oral corticosteroid and methotrexate medication \[still on TCZ\]), and Level 4 (clinical remission off all anti-inflammatory medications \[still on TCZ\]). Number of participants at each clinical remission level was reported.

    Time frame: Weeks 24, 36, 48, 72, and 108

  9. Number of Participants With a Minimally Important Improvement in the Childhood Health Assessment Questionnaire-Disability Index

    The CHAQ-DI included questions on dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. The disability index (DI) of the original CHAQ was graded on 4-point categorical scales of 30 items grouped into 8 domains of physical function. The highest scoring item in each domain determined the score for that domain. The score for the disability index was the mean of domain scores ranging from 0 to 3 (0 = without any difficulty and 3 = unable to do) with higher scores meaning higher disability. Minimally important improvement in CHAQ-DI was defined as a change from baseline of WA19977 core study (Day 1/Visit 1) \>=0.13 at each visit.

    Time frame: Weeks 12, 24, 36, 48, 60, 72, 84, and 108

  10. Number of Joints With Limitation of Motion

    The most frequent symptom reported by most participants was a limitation of motion (LOM) of joints and it was determined by physical examination. The mean joints with limitation of motion were reported.

    Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108

  11. Number of Joints With Active Range of Motion

    The active range of motion joints was counted by physical examination and mean joints was reported.

    Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108

  12. Number of Swollen Joints

    The swollen joints was counted by physical examination and mean swollen joints were reported.

    Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108

  13. Number of Painful Joints

    The painful joints were counted by physical examination and mean painful joints was reported.

    Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108

  14. Physician's Global Assessment of Disease Activity

    The Physician's global assessment of disease activity was recorded on a 0 to 100 mm horizontal VAS where score 0 represented 'arthritis inactive' (i.e., symptom-free and no arthritis symptoms) and score 100 represented 'arthritis very active' (higher score indicate worsening of disease).

    Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108

  15. Parent/Patient's Global Assessment of Disease Activity

    Parent/patient global assessment of disease activity was performed using 0 to 100 mm VAS, and higher the score of VAS, worse the disease status (0= absence of activity or sign or symptom; 100= maximal activity or signs or symptoms). No disease activity was defined as VAS \<=10 mm.

    Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108

  16. Parent/Patient's Discomfort Index (Pain)

    Participants or parents rated participant's pain by placing a horizontal line on a VAS of 0 (no pain) - 100 mm (unbearable pain). To describe the pain, a cut-off at 10 mm was used, and VAS \<10 mm was defined as no pain.

    Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108

07

Results

Posted Nov 2, 2016

Participant flow

A total of seven participants who completed the core study WA19977 were enrolled in this extension study conducted from 13 February 2012 to 15 January 2014 at four centers in France.

Participant flow — Overall Study
MilestoneTocilizumab (8 mg/kg)
Started7
Completed7
Not completed0

Outcome measures

PrimaryNumber of Participants With Any Adverse Events and Any Serious Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.

Time frame:
Approximately 2 years
Reported as:
Number · participants
Number of Participants With Any Adverse Events and Any Serious Adverse Events
participantsTocilizumab (8 mg/kg)
Any AEs7
Any SAEs0
PrimaryNumber of Participants With Adverse Events of Special Interest

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. The AEs of special interests included gingival bleeding, tooth abscess, acarodermatitis, ear infection, gastroenteritis, herpes zoster ophthalmic, lice infestation, nasopharyngitis, oral fungal infection, oral herpes, pharyngitis, rhinitis, sinusitis, tonsillitis, tracheitis, tracheobronchitis, urinary tract infection, menorrhagia, asthma, epistaxis, and hematoma.

Time frame:
Approximately 2 years
Reported as:
Number · participants
Number of Participants With Adverse Events of Special Interest
participantsTocilizumab (8 mg/kg)
Gingival bleeding2
Tooth abscess2
Acarodermatitis1
Ear infection1
Gastroenteritis1
Herpes zoster ophthalmic1
Lice infestation1
Nasopharyngitis1
Oral fungal infection1
Oral herpes1
Pharyngitis1
Rhinitis1
Sinusitis1
Tonsillitis1
Tracheitis1
Tracheobronchitis1
Urinary tract infection1
Menorrhagia1
Asthma1
Epistaxis1
Hematoma1
PrimaryNumber of Participants With Adverse Events Related to Tocilizumab

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. Relatedness of any AEs was reported as possibly related, probably related, or remotely related to TCZ.

Time frame:
Approximately 2 years
Reported as:
Number · participants
Number of Participants With Adverse Events Related to Tocilizumab
participantsTocilizumab (8 mg/kg)
AEs possibly related to TCZ5
AEs probably related to TCZ2
AEs remotely related to TCZ1
SecondaryMean Exposure to Study Treatment

Participants received TCZ for Week 104 or when TCZ was commercially available for pcJIA participants, whichever comes first in France. The mean TCZ exposure (time from first to last administration) was reported.

Time frame:
Approximately 2 years
Reported as:
Mean · Months
Mean Exposure to Study Treatment
MonthsTocilizumab (8 mg/kg)
Mean Exposure to Study Treatment17.08 ± 1.55
SecondaryMean Duration of Study Follow-Up

The participants were followed-up from Day 1 to last visit date (approximately 2 years). Mean time for which participants were followed up in the study was reported.

Time frame:
Approximately 2 years
Reported as:
Mean · Months
Mean Duration of Study Follow-Up
MonthsTocilizumab (8 mg/kg)
Mean Duration of Study Follow-Up21.08 ± 1.64
SecondaryNumber of Participants With AEs Leading to TCZ Modification, AEs Leading to Death, Anaphylaxis or Serious Hypersensitivity and Deaths

Number of participants with AEs leading to TCZ modification, AEs leading to death, anaphylaxis or serious hypersensitivity, and deaths were reported.

Time frame:
Approximately 2 years
Reported as:
Number · participants
Number of Participants With AEs Leading to TCZ Modification, AEs Leading to Death, Anaphylaxis or Serious Hypersensitivity and Deaths
participantsTocilizumab (8 mg/kg)
AEs leading to TCZ modification2
AEs leading to death0
Anaphylaxis or serious hypersensitivity0
Death0
SecondaryNumber of Participants With Clinically Significant Abnormal Laboratory Parameters

Clinically significant abnormal parameters included eosinophil count, alanine aminotransferase, total bilirubin, and protein and blood in urine. Number of participants with these abnormal lab parameters was reported.

Time frame:
Approximately 2 years
Reported as:
Number · participants
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
participantsTocilizumab (8 mg/kg)
Eosinophil count1
Alanine aminotransferase1
Total bilirubin1
Protein and blood in urine2
SecondaryNumber of Participants With Abnormality in Physical Examinations

Participants with abnormal physical examinations of ear, nose and throat (asthma); extremities (synovitis, sequelae with flexion of the 5th right proximal interphalangeal joint, hallux valgus, deviations of metatarsophalangeal joints, and callus under metatarsal head); lung (mild bronchospasm); skin (vitiligo and hematoma, fatty subcutaneous infiltration on the neck, cutaneous eruption, and scalp pediculosis); and musculoskeletal system (discomfort in right hip) were reported.

Time frame:
Approximately 2 years
Reported as:
Number · participants
Number of Participants With Abnormality in Physical Examinations
participantsTocilizumab (8 mg/kg)
Ear, nose and throat1
Extremities1
Lung1
Musculoskeletal system1
Skin3
SecondaryNumber of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology Response 50/70

The Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) is comprised of six components: Maximum number of joints with active arthritis; Number of joints with limitation of movement; Erythrocyte Sedimentation Rate (ESR) and/or C-reactive Protein (CRP); Childhood Health Assessment Questionnaire-Disease Index (CHAQ-DI) graded on 4-point scales \[0 = without any difficulty and 3 = unable to do\] of 30 items grouped into 8 domains of physical function; Physician's global assessment of disease activity and Participant's global assessment of overall well-being (both assessed on a 0 to 100 mm Visual Analogue Scale \[VAS\], where score 0 = inactive arthritis and 100 = very active arthritis). A JIA ACR50/70 response is defined as improvement in at least three of the six core components by at least 50 percent (%), or 70%, respectively and no more than one of the remaining core components worsening by more than 30%.

Time frame:
Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Reported as:
Number · participants
Number of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology Response 50/70
participantsTocilizumab (8 mg/kg)
JIA ACR50, Week 12 (n = 5)1
JIA ACR50, Week 24 (n = 5)2
JIA ACR50, Week 36 (n = 6)1
JIA ACR50, Week 48 (n = 5)1
JIA ACR50, Week 60 (n = 5)0
JIA ACR50, Week 72 (n = 2)0
JIA ACR50, Week 84 (n = 1)1
JIA ACR50, Week 108 (n = 6)2
JIA ACR70, Week 12 (n = 5)4
JIA ACR70, Week 24 (n = 5)3
JIA ACR70, Week 36 (n = 6)5
JIA ACR70, Week 48 (n = 5)4
JIA ACR70, Week 60 (n = 5)5
JIA ACR70, Week 72 (n = 2)2
JIA ACR70, Week 84 (n = 1)0
JIA ACR70, Week 108 (n = 6)4
SecondaryNumber of Participants With Inactive Disease

Inactive disease was defined as: 1) No joints with active arthritis (no swollen, painful and lack of motion joints), 2) No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, 3) No active uveitis, 4) ESR and/or CRP within normal range, and 5) No disease activity according to Physician's global assessment of disease activity (\<= 10 millimeters \[mm\] on a VAS). The participant's treating physician provided a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale where score 0 represented 'arthritis inactive' (i.e., symptom-free and no arthritis symptoms) and score 100 represented 'arthritis very active'.

Time frame:
Weeks 24, 36, 48, 72, and 108
Reported as:
Number · participants
Number of Participants With Inactive Disease
participantsTocilizumab (8 mg/kg)
Week 24 (n = 6)1
Week 36 (n = 7)1
Week 48 (n = 6)1
Week 72 (n = 4)1
Week 108 (n = 7)1
SecondaryNumber of Participants Achieving Clinical Remission

Clinical remission was defined as inactive disease observed for at least 6 continuous months. Clinical remission was defined as per medication uptake as: Level 1 (clinical remission on medication), Level 2 (clinical remission off oral corticosteroid medication \[still on TCZ\]), Level 3 (clinical remission off both oral corticosteroid and methotrexate medication \[still on TCZ\]), and Level 4 (clinical remission off all anti-inflammatory medications \[still on TCZ\]). Number of participants at each clinical remission level was reported.

Time frame:
Weeks 24, 36, 48, 72, and 108
Reported as:
Number · participants
Number of Participants Achieving Clinical Remission
participantsTocilizumab (8 mg/kg)
Week 24, Remission level 1 (n = 7)1
Week 36, Remission level 1 (n = 6)5
Week 48, Remission level 1 (n = 6)1
Week 72, Remission level 1 (n = 4)1
Week 108, Remission level 1 (n = 7)1
SecondaryNumber of Participants With a Minimally Important Improvement in the Childhood Health Assessment Questionnaire-Disability Index

The CHAQ-DI included questions on dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. The disability index (DI) of the original CHAQ was graded on 4-point categorical scales of 30 items grouped into 8 domains of physical function. The highest scoring item in each domain determined the score for that domain. The score for the disability index was the mean of domain scores ranging from 0 to 3 (0 = without any difficulty and 3 = unable to do) with higher scores meaning higher disability. Minimally important improvement in CHAQ-DI was defined as a change from baseline of WA19977 core study (Day 1/Visit 1) \>=0.13 at each visit.

Time frame:
Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Reported as:
Number · participants
Number of Participants With a Minimally Important Improvement in the Childhood Health Assessment Questionnaire-Disability Index
participantsTocilizumab (8 mg/kg)
Week 12 (n=7)5
Week 24 (n=7)5
Week 36 (n=7)6
Week 48 (n=7)5
Week 60 (n=7)6
Week 72 (n=3)2
Week 84 (n=1)0
Week 108 (n=7)6
SecondaryNumber of Joints With Limitation of Motion

The most frequent symptom reported by most participants was a limitation of motion (LOM) of joints and it was determined by physical examination. The mean joints with limitation of motion were reported.

Time frame:
Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Reported as:
Mean · joints
Number of Joints With Limitation of Motion
jointsTocilizumab (8 mg/kg)
Day 1 (n=7)11.4 ± 14.3
Week 12 (n=7)9.4 ± 11.9
Week 24 (n=6)6.7 ± 8.4
Week 36 (n=7)8.1 ± 9.5
Week 48 (n=7)8.6 ± 10.5
Week 60 (n=7)10.3 ± 14.8
Week 72 (n=4)8.5 ± 16.3
Week 84 (n=1)31.0 ± NA
Week 108 (n=7)10.6 ± 13.4
SecondaryNumber of Joints With Active Range of Motion

The active range of motion joints was counted by physical examination and mean joints was reported.

Time frame:
Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Reported as:
Mean · joints
Number of Joints With Active Range of Motion
jointsTocilizumab (8 mg/kg)
Day 1 (n=7)2.3 ± 2.5
Week 12 (n=7)1.4 ± 2.3
Week 24 (n=6)2.2 ± 2.2
Week 36 (n=7)1.3 ± 1.8
Week 48 (n=7)2.0 ± 1.9
Week 60 (n=7)2.0 ± 2.2
Week 72 (n=4)0.3 ± 0.5
Week 84 (n=1)0.0 ± NA
Week 108 (n=7)1.1 ± 1.2
SecondaryNumber of Swollen Joints

The swollen joints was counted by physical examination and mean swollen joints were reported.

Time frame:
Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Reported as:
Mean · joints
Number of Swollen Joints
jointsTocilizumab (8 mg/kg)
Day 1 (n=7)1.6 ± 2.1
Week 12 (n=7)1.0 ± 2.2
Week 24 (n=6)1.0 ± 1.7
Week 36 (n=7)0.9 ± 1.5
Week 48 (n=7)1.9 ± 1.8
Week 60 (n=7)1.7 ± 2.2
Week 72 (n=4)0.3 ± 0.5
Week 84 (n=1)0.0 ± NA
Week 108 (n=7)0.7 ± 1.3
SecondaryNumber of Painful Joints

The painful joints were counted by physical examination and mean painful joints was reported.

Time frame:
Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Reported as:
Mean · joints
Number of Painful Joints
jointsTocilizumab (8 mg/kg)
Day 1 (n=7)1.9 ± 2.3
Week 12 (n=7)0.6 ± 0.8
Week 24 (n=6)2.0 ± 2.8
Week 36 (n=7)0.7 ± 1.0
Week 48 (n=7)0.9 ± 1.1
Week 60 (n=7)0.7 ± 1.0
Week 72 (n=4)0.5 ± 1.0
Week 84 (n=1)0.0 ± NA
Week 108 (n=7)2.0 ± 4.0
SecondaryPhysician's Global Assessment of Disease Activity

The Physician's global assessment of disease activity was recorded on a 0 to 100 mm horizontal VAS where score 0 represented 'arthritis inactive' (i.e., symptom-free and no arthritis symptoms) and score 100 represented 'arthritis very active' (higher score indicate worsening of disease).

Time frame:
Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Reported as:
Mean · millimeter (mm)
Physician's Global Assessment of Disease Activity
millimeter (mm)Tocilizumab (8 mg/kg)
Day 1 (n=7)8.6 ± 7.7
Week 12 (n=6)4.2 ± 6.4
Week 24 (n=7)9.3 ± 12.2
Week 36 (n=7)6.7 ± 6.9
Week 48 (n=7)3.7 ± 3.6
Week 60 (n=7)4.0 ± 3.4
Week 72 (n=4)2.8 ± 4.3
Week 84 (n=1)4.0 ± NA
Week 108 (n=7)6.6 ± 7.1
SecondaryParent/Patient's Global Assessment of Disease Activity

Parent/patient global assessment of disease activity was performed using 0 to 100 mm VAS, and higher the score of VAS, worse the disease status (0= absence of activity or sign or symptom; 100= maximal activity or signs or symptoms). No disease activity was defined as VAS \<=10 mm.

Time frame:
Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Reported as:
Mean · mm
Parent/Patient's Global Assessment of Disease Activity
mmTocilizumab (8 mg/kg)
Day 1 (n=7)14.9 ± 27.5
Week 12 (n=7)8.0 ± 12.2
Week 24 (n=7)12.7 ± 23.3
Week 36 (n=7)3.9 ± 6.8
Week 48 (n=7)10.1 ± 17.4
Week 60 (n=7)7.4 ± 8.3
Week 72 (n=3)0.3 ± 0.6
Week 84 (n=1)73.0 ± NA
Week 108 (n=7)12.1 ± 17.8
SecondaryParent/Patient's Discomfort Index (Pain)

Participants or parents rated participant's pain by placing a horizontal line on a VAS of 0 (no pain) - 100 mm (unbearable pain). To describe the pain, a cut-off at 10 mm was used, and VAS \<10 mm was defined as no pain.

Time frame:
Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Reported as:
Mean · mm
Parent/Patient's Discomfort Index (Pain)
mmTocilizumab (8 mg/kg)
Day 1 (n=7)15.0 ± 27.2
Week 12 (n=7)5.6 ± 7.7
Week 24 (n=7)7.7 ± 11.1
Week 36 (n=7)3.0 ± 3.1
Week 48 (n=7)12.9 ± 18.5
Week 60 (n=7)6.4 ± 7.3
Week 72 (n=3)0.7 ± 0.6
Week 84 (n=1)51.0 ± NA
Week 108 (n=7)5.1 ± 9.0

Adverse events

Collected over Approximately 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab (8 mg/kg)—0/7 (0%)7/7 (100%)
Most frequent other events
Showing 10 of 54
Most frequent other events
EventTocilizumab (8 mg/kg)
NeutropeniaBlood and lymphatic system disorders2/7
Abdominal painGastrointestinal disorders2/7
Gingival bleedingGastrointestinal disorders2/7
Tooth abscessInfections and infestations2/7
AsthmaRespiratory, thoracic and mediastinal disorders2/7
Von Willebrand's diseaseCongenital, familial and genetic disorders1/7
ChalazionEye disorders1/7
ConjunctivitisEye disorders1/7
Dental cariesGastrointestinal disorders1/7
Gastrointestinal disorderGastrointestinal disorders1/7

Baseline characteristics

The intent-to-treat (ITT) population included all the participants who had at least one efficacy assessment.

Age, Customized
Age, Customized(participants)Tocilizumab (8 mg/kg)
2 to 11 years3
12 to 17 years2
18 to 64 years2
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab (8 mg/kg)
Female7
Male0
08

Study locations

4 sites
  • Le Kremlin-Bicêtre, 94275, France
  • Montpellier, 34295, France
  • Paris, 75679, France
  • Paris, 75743, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2012
First posted
Aug 28, 2012
Start
Feb 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Nov 2, 2016
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01673919
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 28, 2012
Start date
Feb 2012
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Nov 2, 2016
Last update
Sep 12, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion